Loading...
Loading...
MOR| Name | Value |
|---|---|
| Revenues | 63.8M |
| Cost of Revenue | 15.1M |
| Gross Profit | 48.7M |
| Operating Expense | 98.1M |
| Operating I/L | -51.0M |
| Other Income/Expense | -68.1M |
| Interest Income | 1.3M |
| Pretax | -119.1M |
| Income Tax Expense | 0.5M |
| Net Income/Loss | -119.6M |
MorphoSys AG is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapeutic antibodies for cancer and autoimmune diseases. Its flagship product, Tafasitamab, targets B cell malignancies. The company also develops Pelabresib for myelofibrosis, Felzartamab for anti-PLA2R-positive membranous nephropathy, and CPI-0209 for anti-tumor activity. Additionally, it has partnerships with pharmaceutical companies for the development of Gantenerumab for Alzheimer's disease, Otilimab for rheumatoid arthritis, Tremfya for psoriasis, and MOR210/TJ210 for immuno-oncology and autoimmune diseases.
